Neurosigma Inc (Neurosigma) is a life science company that develops and commercializes trigeminal nerve stimulation technologies for neurologic and psychiatric disorders. The company offers treatments for epilepsy, depression, attention deficit hyperactivity disorder, and post-traumatic stress disorder. It also conducts preclinical research and development, and phase clinical trials. Neurosigma offers Monarch eTNS System for the treatment of pediatric Attention Deficit Hyperactivity Disorder (ADHD). The company's trigeminal nerve stimulation has been investigated as a therapy for epilepsy, depression, attention deficit hyperactivity disorder, and post-traumatic stress disorder, Lennox-Gastaut syndrome and traumatic brain injuries, among others. NeuroSigma is headquartered in Los Angeles, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Neurosigma Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Neurosigma Inc Company Overview
- Neurosigma Inc Company Snapshot
- Neurosigma Inc Pipeline Products and Ongoing Clinical Trials Overview
- Neurosigma Inc - Pipeline Analysis Overview
- Neurosigma Inc - Key Facts
- Neurosigma Inc - Major Products and Services
- Neurosigma Inc Pipeline Products by Development Stage
- Neurosigma Inc Ongoing Clinical Trials by Trial Status
- Neurosigma Inc Pipeline Products Overview
- Deep Brain Stimulation System - Cachexia
- Deep Brain Stimulation System - Cachexia Product Overview
- Deep Brain Stimulation System - Obesity
- Deep Brain Stimulation System - Obesity Product Overview
- DELTA Stent
- DELTA Stent Product Overview
- Generation 2.0 Monarch external Trigeminal Nerve Stimulation (eTNS) System
- Generation 2.0 Monarch external Trigeminal Nerve Stimulation (eTNS) System Product Overview
- Micropatterned TFN Stent
- Micropatterned TFN Stent Product Overview
- Monarch eTNS System - ADHD
- Monarch eTNS System - ADHD Product Overview
- Monarch eTNS System - ADHD Clinical Trial
- Monarch eTNS System - Depression
- Monarch eTNS System - Depression Product Overview
- Monarch eTNS System - Epilepsy
- Monarch eTNS System - Epilepsy Product Overview
- Monarch eTNS System - Lennox-Gastaut Syndrome
- Monarch eTNS System - Lennox-Gastaut Syndrome Product Overview
- Monarch eTNS System - Post-Traumatic Stress Disorder
- Monarch eTNS System - Post-Traumatic Stress Disorder Product Overview
- Monarch eTNS System - Traumatic Brain Injury
- Monarch eTNS System - Traumatic Brain Injury Product Overview
- Next-Generation eTNS System
- Next-Generation eTNS System Product Overview
- sTNS System - Epilepsy
- sTNS System - Epilepsy Product Overview
- Thin Film Nitinol Flow Diverting Stent
- Thin Film Nitinol Flow Diverting Stent Product Overview
- Neurosigma Inc - Key Competitors
- Neurosigma Inc - Key Employees
- Neurosigma Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Neurosigma Inc, Recent Developments
- Jan 18, 2024: NeuroSigma gets green light from FDA for ADHD wearable
- Nov 07, 2023: NeuroSigma Announces FDA 510(k) Submission for Second Generation Monarch eTNS System
- Mar 01, 2023: NeuroSigma announces new telehealth option for patients and caregivers interested in eTNS for pediatric ADHD
- Jan 31, 2023: NeuroSigma announces strategic digital marketing partnership with Data360
- Nov 08, 2022: NeuroSigma announces that enrollment commences in two large, double-blind trials of eTNS for Pediatric ADHD
- Oct 17, 2022: NeuroSigma announces commercial launch of the Monarch eTNS System for the treatment of pediatric ADHD at Annual Meeting of the American Academy of Child and Adolescent Psychiatry
- Sep 27, 2022: NeuroSigma announces receipt of permanent HCPCS codes from CMS for Monarch eTNS System
- Jun 14, 2022: NeuroSigma announces that a team led by UCLA researchers receives NIH grant to conduct a multicenter trial of eTNS for pediatric ADHD
- Apr 07, 2022: NeuroSigma announces King’s College London Team receives MHRA approval to commence largest clinical trial of eTNS for Pediatric ADHD to Date
- Feb 22, 2022: NeuroSigma receives FDA Breakthrough Device Designation for Monarch eTNS System
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Neurosigma Inc Pipeline Products and Ongoing Clinical Trials Overview
- Neurosigma Inc Pipeline Products by Equipment Type
- Neurosigma Inc Pipeline Products by Indication
- Neurosigma Inc Ongoing Clinical Trials by Trial Status
- Neurosigma Inc, Key Facts
- Neurosigma Inc, Major Products and Services
- Neurosigma Inc Number of Pipeline Products by Development Stage
- Neurosigma Inc Pipeline Products Summary by Development Stage
- Neurosigma Inc Ongoing Clinical Trials by Trial Status
- Neurosigma Inc Ongoing Clinical Trials Summary
- Deep Brain Stimulation System - Cachexia - Product Status
- Deep Brain Stimulation System - Cachexia - Product Description
- Deep Brain Stimulation System - Obesity - Product Status
- Deep Brain Stimulation System - Obesity - Product Description
- DELTA Stent - Product Status
- DELTA Stent - Product Description
- Generation 2.0 Monarch external Trigeminal Nerve Stimulation (eTNS) System - Product Status
- Generation 2.0 Monarch external Trigeminal Nerve Stimulation (eTNS) System - Product Description
- Micropatterned TFN Stent - Product Status
- Micropatterned TFN Stent - Product Description
- Monarch eTNS System - ADHD - Product Status
- Monarch eTNS System - ADHD - Product Description
- Monarch eTNS System - ADHD - A Multi-centre, Double-blind, Randomized, Parallel-group, Phase IIb Study to Compare the Efficacy of Real Versus Sham External Trigeminal Nerve Stimulation on Symptoms in Youth with Attention Deficit Hyperactivity Disorder
- Monarch eTNS System - ADHD - Efficacy of External Trigeminal Nerve Stimulation for Treatment of ADHD
- Monarch eTNS System - Depression - Product Status
- Monarch eTNS System - Depression - Product Description
- Monarch eTNS System - Epilepsy - Product Status
- Monarch eTNS System - Epilepsy - Product Description
- Monarch eTNS System - Lennox-Gastaut Syndrome - Product Status
- Monarch eTNS System - Lennox-Gastaut Syndrome - Product Description
- Monarch eTNS System - Post-Traumatic Stress Disorder - Product Status
- Monarch eTNS System - Post-Traumatic Stress Disorder - Product Description
- Monarch eTNS System - Traumatic Brain Injury - Product Status
- Monarch eTNS System - Traumatic Brain Injury - Product Description
- Next-Generation eTNS System - Product Status
- Next-Generation eTNS System - Product Description
- sTNS System - Epilepsy - Product Status
- sTNS System - Epilepsy - Product Description
- Thin Film Nitinol Flow Diverting Stent - Product Status
- Thin Film Nitinol Flow Diverting Stent - Product Description
- Neurosigma Inc, Key Employees
- Neurosigma Inc, Subsidiaries
- Glossary
- Neurosigma Inc Pipeline Products by Equipment Type
- Neurosigma Inc Pipeline Products by Development Stage
- Neurosigma Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- InnovaQuartz LLC
- NeuroMEDx
- CJPS Medical Systems, LLC
- NeuroMEDx
- InnovaQuartz LLC
- CJPS Medical Systems, LLC
